Search the database for deliberate release of GM medicinal products
| EU record number |
Title |
Company / Sponsor |
Treated organism |
Genetic modification |
| 68284528MMY2003 |
A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with R |
Janssen-Cilag International NV |
Humans |
Autologous T cells expressing BCMA (B-cell maturation antigen)-CAR |
| 68284528MMY2001 |
A Phase 1b-2, open-label study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) therapy directed against BCMA in subjets with relapsed or refractory multiple myeloma. Protocol 68284528MMY2001 |
Janssen-Cilag International NV |
Humans |
B-cell maturation antigen (BCMA)-chimeric antigen receptor |
| Only notified under the "contained use" procedure. Dossier submitted on
. |
An Open-label Randomized Phase 1b/2 Study of the Efficacy and Safety of JNJ-64041757, a Live Attenuated Listeria monocytogenes Immunotherapy, in Combination with Nivolumab Versus Nivolumab Monotherapy in Subjects With Advanced Adenocarcinoma of the Lung |
Janssen-Cilag International NV |
Humans |
Genetically modified, live attenuated Listeria monocytogenes (Lm ΔactA/ΔinlB) |
| Only notified under the "contained use" procedure. Dossier submitted on
. |
Efficacy and safety of bilateral intravitreal injection of GS010: a randomized, double-masked, placebo-controlled trial in subjects affected with G11778A ND4 leber hereditary optic neuropathy for up to one year. |
GenSight Biologics |
Humans |
human wild-type MT-NDA (mitochondrial NADH Dehydrogenase 4) |
